Justin D. Floyd

2.1k total citations
17 papers, 846 citations indexed

About

Justin D. Floyd is a scholar working on Oncology, Pathology and Forensic Medicine and Dermatology. According to data from OpenAlex, Justin D. Floyd has authored 17 papers receiving a total of 846 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 4 papers in Pathology and Forensic Medicine and 3 papers in Dermatology. Recurrent topics in Justin D. Floyd's work include Peptidase Inhibition and Analysis (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chemotherapy-related skin toxicity (3 papers). Justin D. Floyd is often cited by papers focused on Peptidase Inhibition and Analysis (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chemotherapy-related skin toxicity (3 papers). Justin D. Floyd collaborates with scholars based in United States, Malaysia and United Kingdom. Justin D. Floyd's co-authors include Michael C. Perry, Irfan Ali Mirza, Duc T. Nguyen, Donald C. Doll, Qaiser Bashir, Carol J. Fabian, Nancy E. Davidson, Carolyn D. Runowicz, Judy E. Garber and Sandhya Pruthi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Justin D. Floyd

17 papers receiving 819 citations

Peers

Countries citing papers authored by Justin D. Floyd

Since Specialization

Citations

This map shows the geographic impact of Justin D. Floyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin D. Floyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin D. Floyd more than expected).

Fields of papers citing papers by Justin D. Floyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin D. Floyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin D. Floyd. The network helps show where Justin D. Floyd may publish in the future.

Co-authorship network of co-authors of Justin D. Floyd

This figure shows the co-authorship network connecting the top 25 collaborators of Justin D. Floyd. A scholar is included among the top collaborators of Justin D. Floyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin D. Floyd. Justin D. Floyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer 2020 ·JAMA Oncology ·Catherine Van Poznak, Joseph M. Unger, Amy K. Darke, Carol M. Moinpour, Bagramian Er, Mark M. Schubert, Lisa Hansen, Justin D. Floyd, Shaker R. Dakhil, Danika L. Lew, James L. Wade, Michael Fisch, N. Lynn Henry, Dawn L. Hershman, Julie R. Gralow	49
2	A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013 2020 ·Journal of Patient-Reported Outcomes ·Siu‐Fun Wong, Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, (unknown), Anna Moseley, Kathryn B. Arnold, Mario R. Velasco, Justin D. Floyd, Benjamin Esparaz, Afsaneh Barzi, Heinz‐Josef Lenz, Marianna Koczywas, Shaker R. Dakhil, Gary V. Burton, Michael Fisch, N. Lynn Henry, Dawn L. Hershman, Carol M. Moinpour	3
3	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update 2019 ·Journal of Clinical Oncology ·Kala Visvanathan, Carol J. Fabian, Elissa Bantug, Abenaa M. Brewster, Nancy E. Davidson, Andrea DeCensi, Justin D. Floyd, Judy E. Garber, Erin Hofstatter, Seema A. Khan, Maria C. Katapodi, Sandhya Pruthi, (unknown), Carolyn D. Runowicz, Mark R. Somerfield	117
4	The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity 2019 ·JACC CardioOncology ·Lori M. Minasian, Eileen Dimond, (unknown), Bishow B. Adhikari, Richard M. Fagerstrom, Carol J. Fabian, Justin D. Floyd, Joseph M. Unger, Pamela S. Douglas, Karen M. Mustian, Eric J. Chow, Steven E. Lipshultz, W. Gregory Hundley, Saro H. Armenian, Bonnie Ky	14
5	Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211. 2019 ·Journal of Clinical Oncology ·Catherine Van Poznak, Joseph M. Unger, Amy K. Darke, Carol M. Moinpour, Bagramian Er, Mark M. Schubert, Lisa Hansen, Justin D. Floyd, Shaker R. Dakhil, Danika L. Lew, James L. Wade, Michael Fisch, N. Lynn Henry, Dawn L. Hershman, Julie R. Gralow	6
6	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study 2018 ·The Lancet Haematology ·Paul M. Barr, Hongli Li, Richard Burack, Michael LeBlanc, Sonali M. Smith, Ajay K. Gopal, Justin D. Floyd, Daniel O. Persky, Oliver W. Press, Richard I. Fisher, Jonathan W. Friedberg	14
7	Acute Angle Closure Precipitated by Hemorrhage and Necrosis of a Large Uveal Melanoma in the Setting of Systemic Immunomodulatory Therapy 2017 ·Ocular Oncology and Pathology ·Chau Pham, (unknown), Bradley T. Smith, Justin D. Floyd, John B. Holds	1
8	PhaseIItrial of R‐CHOPplus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma:SWOGS0601 2015 ·British Journal of Haematology ·Brian G. Till, Hongli Li, Steven H. Bernstein, Richard I. Fisher, Richard Burack, Lisa M. Rimsza, Justin D. Floyd, (unknown), Dennis F. Moore, Olga Pozdnyakova, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg	33
9	Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601 2014 ·Blood ·Brian G. Till, Hongli Li, Steven H. Bernstein, Richard I. Fisher, Richard Burack, Lisa M. Rimsza, Justin D. Floyd, (unknown), Dennis F. Moore, Michael LeBlanc, Jonathan W. Friedberg	10
10	Multicentric Giant Cell Tumor of the Fourth and Fifth Metacarpals with Lung Metastases 2013 ·Hand ·Nash H. Naam, Steven Jones, Justin D. Floyd, (unknown)	15
11	Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial 2010 ·Journal of Thoracic Oncology ·Barbara J. Gitlitz, James Moon, Bonnie S. Glisson, (unknown), Martin J. Bury, Justin D. Floyd, Thomas K. Schulz, (unknown), (unknown), David R. Gandara	49
12	Small Cell Carcinoma of Unknown Primary 2007 ·Seminars in Oncology ·(unknown), Justin D. Floyd	22
13	Hepatotoxicity of Chemotherapy 2006 ·Seminars in Oncology ·Justin D. Floyd, Irfan Ali Mirza, (unknown), Michael C. Perry	182
14	Pulmonary Toxicity of Chemotherapy 2006 ·Seminars in Oncology ·(unknown), Justin D. Floyd, Michael C. Perry	54
15	Cardiotoxicity of Cancer Therapy 2005 ·Journal of Clinical Oncology ·Justin D. Floyd, Duc T. Nguyen, (unknown), Qaiser Bashir, Donald C. Doll, Michael C. Perry	268
16	Patients With Unusual Bladder Malignancies and a Rare Cause of Splenomegaly 2005 ·Journal of Clinical Oncology ·Justin D. Floyd, (unknown), Edward R. Sauter, Michael C. Perry, Donald C. Doll	3
17	A clinicopathologic comparison of malignant fibrous histiocytoma and liposarcoma. 1989 ·PubMed ·Suzanne S. Spanier, Justin D. Floyd	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact